CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares fell 3.8% on Wednesday . The stock traded as low as $2.17 and last traded at $2.25, with a volume of 192,521 shares traded. The stock had previously closed at $2.34.

Several brokerages have recently weighed in on CBAY. Zacks Investment Research raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. HC Wainwright reiterated a “buy” rating on shares of CymaBay Therapeutics in a research report on Thursday, May 12th. Finally, Roth Capital started coverage on CymaBay Therapeutics in a research report on Friday, July 1st. They set a “buy” rating for the company.

The stock’s market capitalization is $52.99 million. The company has a 50 day moving average of $1.87 and a 200 day moving average of $1.79.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. On average, equities analysts predict that CymaBay Therapeutics Inc. will post ($1.20) EPS for the current fiscal year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.